Control your drug costs with AI driven precision
In today's complex and fast-changing healthcare landscape, managing the rising costs of drugs is critical. CuraFi’s first-of-its-kind risk analysis and cost management solutions help you regain control and significantly reduce costs.
Talk With an ExpertIRA has shifted risk to
providers and plans
IRA has shifted risk to providers and plans
CuraFi helps identify and manage the largest opportunities for drug savings, addressing the coverage gap that existed prior to the IRA changes including copay smoothing, catastrophic reinsurance, and managing Maximum Fair Price (MFP) drugs.
Part B to Part D Shifts
Biosimilar Utilization
Provider Enablement
Guaranteed Savings
Care Coordination:
Problem:
- Rebate revenue from CMS MFP-negotiated drugs is expected to largely disappear.
- M3P copay smoothing will lead to an increase in drug utilization.
- With the coverage gap eliminated, overall spending is expected to rise.
Part B to Part D Shifts
Biosimilar Utilization
Provider Enablement
Guaranteed Savings
Care Coordination:
Problem:
- Rebate revenue from CMS MFP-negotiated drugs is expected to largely disappear.
- M3P copay smoothing will lead to an increase in drug utilization.
- With the coverage gap eliminated, overall spending is expected to rise.
The data, analytics, and strategic support you need to take control
Curafi can benchmark your data to comparable plans, identify over/under indexed drugs, and help with your upcoming bids.
Learn more
The latest from CuraFi
Learn how CuraFi can help
Reach out today to see how your organization can benefit from CuraFi's drug risk and cost management solution.